Description:
Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. Preliminary evidence suggests that ABT-494 may spare Jak2 and Jak3 dependent signaling compared to tofacitinib. Phase II for the treatment of Atopic dermatitis and Crohn's disease, Phase III for the treatment of Rheumatoid arthritis and Ulcerative colitis was on-going.
- Molecular Weight: 380.37
- Molecular Formula: C17H19F3N6O
Purity: 98%
Canonical SMILES:
CC[C@@H]1CN(C[C@@H]1c2cnc3cnc4[nH]ccc4n23)C(=O)NCC(F)(F)F
InChI:
1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
InChIKey: WYQFJHHDOKWSHR-MNOVXSKESA-N
- Solubility: Soluble in DMSO
- Appearance: Powder
- Application: Rheumatoid arthritis; Ulcerative colitis;Atopic dermatitis; Crohn's disease
- Storage: -20°C Freezer
Synonyms:
UNII-4RA0KN46E0;ABT494;(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
More details are to be found on supplier website
